MedTrace Logo

IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease

NCT00523159 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2012-07-10

No results posted yet for this study

Summary

This study was conducted in order to evaluate the efficacy and safety of the cancer vaccine IMA901 and GM-CSF as adjuvant in the treatment of advanced renal cell carcinoma.

Patients received vaccination with GM-CSF followed by IMA901 during the study period of 9 months. Patients received pre-treatment with a single i.v. infusion of cyclophosphamide prior to the first vaccination.

Conditions

Interventions

DRUG

Endoxana, IMA901, Leukine

a single i.v. infusion of Cyclophosphamid and then patients received vaccination therapy with intradermal (i.d.) injections of GM-CSF followed by i.d. injections of IMA901

DRUG

IMA901 and Leukine

Intradermal injection of GM-CSF followed by intradermal injection of IMA901

Sponsors & Collaborators

  • Immatics Biotechnologies GmbH

    lead INDUSTRY

Principal Investigators

  • Alexandra Kirner, PhD · Immatics Biotechnologies GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • Austria
  • Bulgaria
  • Germany
  • Hungary
  • Poland
  • Romania
  • Slovakia
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00523159 on ClinicalTrials.gov